Status:
TERMINATED
Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Princess Margaret Hospital, Canada
Mount Sinai Hospital, Canada
Conditions:
Chronic Myeloid Leukemia
Gastrointestinal Stromal Cell Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
In order to distinguish between clonal instability driven by imatinib in CML and actual changes with secondary clones induced by imatinib we would like to investigate the karyotype of non-CML patients...
Detailed Description
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia (Ph) chromosome - a t(9:22) translocation that results in the production of a BCR/ABL ...
Eligibility Criteria
Inclusion
- GIST patient on Imatinib for more than 12 months
Exclusion
- nil
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT00461929
Start Date
February 1 2005
End Date
December 1 2008
Last Update
February 13 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 2M9
2
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9